John L. North

Hill, Kertscher & Wharton (Atlanta)
Lawyer (Partner)

John North focuses his practice on intellectual property and other technology litigations with an emphasis on patents, trademarks and trade secrets. A significant number of John’s patent cases have involved unfair competition claims, including PRE and Walker Process claims as well as patent misuse and Lanham Act claims. John also has experience in other areas of complex litigation, including securities, professional liability and employment. Many international corporations have relied on John to take the lead counsel role in major patent litigation, including a major telecommunications company, a major cable company, an electronics focused major entertainment company, some of the world’s largest pharmaceutical corporations and a cutting-edge minerals technology company. John spends considerable time in court handling trials and hearings, and takes a “hands on” approach to his cases. He has handled cases involving a wide range of technologies including cable, telecommunications, interactive program guides, consumer products, electronic coupons, computerized healthcare information systems and other electronics, pharmaceuticals, various chemical products, paint, textile dye processes and a variety of minerals technologies. Prior to joining Hill, Kertscher & Wharton, LLP, John was a partner at Kasowitz Benson Torres & Friedman LLP and chaired the Intellectual Property Group at Sutherland Asbill & Brennan LLP.

Linked author

Sutherland

Articles

239 Bulletin

John L. North, William L. Warren A US Court of Appeals holds that antitrust law is not implicated provided that the terms of “pay for delay” settlements between the brand name and generic pharma companies are within the scope of the patent (Valley Drug/Abbott Laboratories)

239

A recent 11th Circuit case, Valley Drug Co. v. Geneva Pharmaceuticals, Inc., sheds light on the complex intersection of patent and antitrust law in the context of a settlement agreement between a name brand pharmaceutical manufacturer and two allegedly infringing generic manufacturers that (...)

Send a message